- Home
- GTEC vs BLRX Comparison
GTEC vs BLRX Comparison
Compare GTEC & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTEC | BLRX |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 17.1M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | GTEC | BLRX |
|---|---|---|
| Price | $1.01 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 223.8K | 25.9K |
| Earning Date | 11-07-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $86,168,664.00 | $12,735,000.00 |
| Revenue This Year | $5.64 | N/A |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | $1.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $2.30 |
| 52 Week High | $2.92 | $14.70 |
Technical Indicators
Market Signals| Indicator | GTEC | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 44.04 |
| Support Level | $0.92 | $3.12 |
| Resistance Level | $1.09 | $3.86 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 25.71 | 25.37 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.